Jon Wigginton, an expert in immunotherapy drug development, has joined the board of Pathios Therapeutics Ltd as a non-executive director. Dr Wigginton brings over 25 years of corporate and research experience in clinical oncology, including leadership positions at Bristol Myers Squibb where he led early clinical development of the company's immuno-oncology portfolio. He is currently president of research and development at Bright Peak Therapeutics, a clinical-stage biotechnology company.
Pathios is working on a programme to counteract the polarisation of immune cells that can occur in the tumour microenvironment. The company is advancing its lead asset PTT-4256, a small molecule inhibitor of a G protein-coupled receptor called GPR65, through an ongoing clinical trial in solid tumours.
Pathios Therapeutics announced the appointment on 24 September 2025.
Copyright 2025 Evernow Publishing Ltd.